

Appendix 16 - Payment by Results guidance

This is the most recent outline of PbR for CF. Taken from 2019/2020 National Tariff Payment System, NHS England & NHS Improvement.

https://improvement.nhs.uk/documents/4980/1920_National_Tariff_Payment_System.pdf

Cystic fibrosis pathway payment

124. The cystic fibrosis (CF) pathway currency is a complexity-adjusted yearly banding system with seven bands of increasing complexity of patient need. The tariff relates to a year of care. The pathway does not distinguish between adults and children.

125. The pathway payments cover all treatment directly related to CF for a patient during the financial year. This includes:

- admitted patient care and outpatient attendances (whether delivered in a specialist centre or under shared network care arrangements)
- home care support, including home intravenous antibiotics supervised by the CF service, home visits by the multidisciplinary team to monitor a patient's condition, eg management of totally implantable venous access devices (TIVADs), collection of mid-course aminoglycoside blood levels and general support for patient and carers
- intravenous antibiotics provided during inpatient spells
- annual review investigations.

126. The cystic fibrosis pathway currency was designed to support specialist cystic fibrosis multidisciplinary teams to provide care in a seamless, patient-centred manner, removing any incentives to hospitalise patients whose care can be well managed in the community and in their homes. Furthermore, it allows early intervention (following international guidelines) to prevent disease progression – for example, through the use of antipseudomonal inhaled/nebulised antibiotics and mucolytic therapy.

127. Further information is provided in Annex A.

Annex A can be found –

<https://improvement.nhs.uk/resources/national-tariff/#h2-annexes>